Brian Miles
Overview
Explore the profile of Brian Miles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
328
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andring L, Krc R, Paradise E, Li B, Baghwala A, Miles B, et al.
Brachytherapy
. 2025 Feb;
PMID: 40011081
Purpose: Biochemical recurrence (BCR) occurs in approximately 30% of men after upfront prostatectomy (RP) for prostate cancer. Salvage fossa brachytherapy offers a promising local treatment option. Here we describe a...
2.
Sridhar S, Abouelfetouh Z, Codreanu I, Gupta N, Zhang S, Efstathiou E, et al.
Prostate
. 2024 Dec;
85(5):413-423.
PMID: 39702937
Background: Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) in the current Prostate Imaging-Reporting and Data System version 2.1 (PI-RADS v2.1) is considered optional, with primary scoring based on T2-weighted imaging...
3.
Ding Y, Bu P, Assylbekova B, Ruder S, Miles B, Sayeeduddin M, et al.
Hum Pathol
. 2023 Dec;
144:1-7.
PMID: 38159867
Semiquantitative reactive stromal grading has been shown to be a predictor of biochemical recurrence and prostate cancer (PCa) specific death. It has been extensively validated. In this study we tested...
4.
Ruder S, Gao Y, Ding Y, Bu P, Miles B, De Marzo A, et al.
Hum Pathol
. 2022 Feb;
122:84-91.
PMID: 35176252
To develop and validate a new tissue-based biomarker that improves prediction of outcomes in localized prostate cancer by quantifying the host response to tumor. We use digital image analysis and...
5.
Ding Y, Lee M, Gao Y, Bu P, Coarfa C, Miles B, et al.
Prostate
. 2020 Oct;
81(1):58-71.
PMID: 33022812
Background: Nerves are key factors in prostate cancer (PCa) progression. Here, we propose that neuropeptide Y (NPY) nerves are key regulators of cancer-nerve interaction. Methods: We used in vitro models...
6.
Rehman A, El-Zaatari Z, Han S, Shen S, Ayala A, Miles B, et al.
Ann Diagn Pathol
. 2020 Sep;
49:151611.
PMID: 32956915
The 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system subdivides prostatic pT3 tumors into pT3a, which includes cases with extraprostatic extension (EPE) and pT3b, which...
7.
Khavari R, Hernandez N, Karmonik C, Shi Z, Miles B, Gonzalez R
Contemp Clin Trials Commun
. 2019 Dec;
17:100498.
PMID: 31886434
Introduction And Background: Benign Prostatic Hyperplasia (BPH) affects the micturition cycle. Lower urinary tract symptoms (LUTS) refers to storage symptoms such as urinary frequency, urgency, urge urinary incontinence and nocturia....
8.
Miles B, Ittmann M, Wheeler T, Sayeeduddin M, Cubilla A, Rowley D, et al.
Arch Pathol Lab Med
. 2019 Mar;
143(5):565-570.
PMID: 30865488
Context.—: The combination of grading and staging is the basis of current standard of care for prediction for most cancers. D. F. Gleason created the current prostate cancer (PCa) grading...
9.
Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, et al.
Prostate
. 2017 Nov;
78(2):128-139.
PMID: 29131367
Background: Nerves are key factors in prostate cancer (PCa), but the functional role of innervation in prostate cancer is poorly understood. PCa induced neurogenesis and perineural invasion (PNI), are associated...
10.
Vitro K, BenDor T, Jordanova T, Miles B
Sci Total Environ
. 2017 Apr;
603-604:709-727.
PMID: 28359567
Although non-point source (NPS) pathogen pollution is a leading cause of stream impairment in the United States, the sources of NPS pollution are often difficult to ascertain. While previous studies...